Camille Hylton, MD
Ophthalmology · Tempe, AZNPI 1629019732
Payments from drug & device makers
Across 89 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$447
- Notal Vision, Inc.$402
- Alcon$242
- Sun Pharmaceutical Industries Inc.$174
- Bausch & Lomb Americas Inc.$155
- Aerie Pharmaceuticals, Inc.$137
- plus $679 from 15 others
What the payments were for
- Speaking & faculty fees$40218%
- Food & beverage$1,73778%
- Education$984%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 21 | $447 |
| Notal Vision, Inc. | 1 | $402 |
| Alcon | 13 | $242 |
| Sun Pharmaceutical Industries Inc. | 7 | $174 |
| Bausch & Lomb Americas Inc. | 8 | $155 |
| Aerie Pharmaceuticals, Inc. | 7 | $137 |
| Novartis | 5 | $79 |
| Thea Pharma Inc. | 4 | $76 |
| Kala Pharmaceuticals, Inc. | 3 | $71 |
| Rayner Intraocular Lenses Limited | 2 | $59 |
| Amgen | 3 | $58 |
| Rxsight Inc | 2 | $56 |
| Apellis Pharmaceuticals, Inc. | 2 | $55 |
| Sight Sciences, Inc. | 3 | $55 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $36 |
| LKC Technologies, Inc. | 1 | $35 |
| Shire North American Group Inc | 1 | $28 |
| Iridex Corporation | 1 | $27 |
| Akorn Operating Company LLC | 1 | $24 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| Katena Products, Inc. (dba Corza Medical) | 1 | $2 |
How this compares
$2,237 in reported general payments places this provider in the 55th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 323 | $178,522 |
| RhopressaNetarsudil Mesylate | 160 | $72,638 |
| CombiganBrimonidine Tartrate/Timolol | 122 | $63,677 |
| VyzultaLatanoprostene Bunod | 120 | $48,692 |
| RocklatanNetarsudil Mesylat/Latanoprost | 92 | $46,513 |
| RestasisCyclosporine | 43 | $41,036 |
| Alphagan PBrimonidine Tartrate | 64 | $31,269 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 144 | $26,997 |
| Brimonidine Tartrate | 510 | $22,412 |
| Latanoprost | 1,357 | $16,487 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 45 | $15,630 |
| Brinzolamide | 75 | $15,531 |
| Travoprost | 78 | $14,314 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 547 | $12,484 |
| Cyclosporine | 20 | $10,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $447 | $314,505552 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $137 | $119,151252 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $155 | $48,692120 claims |
| AlconSimbrinza | $242 | $15,63045 claims |
| Thea Pharma Inc.Iyuzeh | $76 | $3,80011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Tempe
- Jon KontiTempe$15K
- Mark BarakatScottsdale$2.9M
- Michael DepenbuschChandler$2.3M
- Ramin SchadluPhoenix$1.8M
- Gerald WalmanSun City$1.7M
- John CasonPhoenix$1.7M
- George ReissGlendale$1.3M
- Warren HillMesa$1.2M
- Benjamin HellerPhoenix$1.1M
- Neal PalejwalaPhoenix$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.